Parenteral Drugs (India) (NSE:PDPL) Ending Cash Position: ₹0.00 Mil (As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Ending Cash Position?

Parenteral Drugs (India) NSE:PDPL 4 Ending Cash Position is ₹0.00 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s Ending Cash Position for the quarter that ended in Mar. 2022 was ₹0.00 Mil.

Parenteral Drugs (India)'s annual Ending Cash Position declined from Mar. 2020 (₹1.08 Mil) to Mar. 2021 (₹0.57 Mil) and declined from Mar. 2021 (₹0.57 Mil) to Mar. 2022 (₹0.00 Mil).

Parenteral Drugs (India) Ending Cash Position Related Terms

Parenteral Drugs (India) Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Ending Cash Position Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.95 1.08 0.57 0.00

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Parenteral Drugs (India)'s Ending Cash Position for the fiscal year that ended in Mar. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.57000000000008+-0.56900000000008
=0.00

Parenteral Drugs (India)'s Ending Cash Position for the quarter that ended in Mar. 2022 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹0.00 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Ending Cash Position of ₹0.00 Mil as of Mar. 2022. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Ending Cash Position too high?
Parenteral Drugs (India)'s current Ending Cash Position is ₹0.00 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Ending Cash Position compare to ZTS and CTLT?
Parenteral Drugs (India)'s Ending Cash Position of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Ending Cash Position is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Ending Cash Position of ₹0.00 Mil. The current Ending Cash Position is ₹0.00 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Ending Cash Position is ₹0.00 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price